CYP2J2 and EETs Protect against Oxidative Stress and Apoptosis in Vivo and in Vitro Following Lung Ischemia/Reperfusion

Cell Physiol Biochem. 2014;33(6):1663-80. doi: 10.1159/000362950. Epub 2014 May 16.

Abstract

Background: Cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acids to epoxyeicosatrienoic acids (EETs). EETs exert various biological effects, including anti-inflammatory, anti-apoptotic, pro-proliferation, pro-angiogenesis, anti-oxidation, and anti-fibrosis effects. However, little is known about the role of CYP2J2 and EETs in lung ischemia/reperfusion injury. In this study, we examined the effects of exogenous EETs or CYP2J2 overexpression on lung ischemia/reperfusion injury in vivo and in vitro.

Methods and results: CYP2J2 gene was stably transfected into rat lungs via pcDNA3.1-CYP2J2 plasmid delivery, resulting in increased EETs levels in the serum and lung. A rat model of lung ischemia/reperfusion injury was developed by clamping the left lung hilum for 1 hour, followed by reperfusion for 2 hours. We found that CYP2J2 overexpression markedly decreased the levels of oxidative stress and cell apoptosis in lung tissues induced by ischemia/reperfusion. Moreover, we observed that exogenous EETs, or CYP2J2 overexpression, enhanced cell viability, decreased intracellular reactive oxygen species (ROS) generation, inhibited mitochondrial dysfunction, and attenuated several apoptotic signaling events in a human pulmonary artery endothelial cells (HPAECs)-based anoxia/reoxygenation model. These apoptotic events included activation of NADPH oxidase, collapse of mitochondrial transmembrane potential, and activation of pro-apoptotic proteins and caspase-3. These effects were mediated, at least partially, by the PI3K/Akt signaling pathway.

Conclusion: These results reveal that CYP2J2 overexpression and exogenous EETs can protect against oxidative stress and apoptosis following lung ischemia/reperfusion in vivo and in vitro, suggesting that increasing the level of EETs may be a novel promising strategy to prevent and treat lung ischemia/reperfusion injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8,11,14-Eicosatrienoic Acid / analogs & derivatives
  • 8,11,14-Eicosatrienoic Acid / metabolism
  • 8,11,14-Eicosatrienoic Acid / pharmacology*
  • Animals
  • Apoptosis / drug effects*
  • Apoptosis / genetics
  • Blotting, Western
  • Cell Hypoxia
  • Cell Survival / drug effects
  • Cell Survival / genetics
  • Cells, Cultured
  • Cytochrome P-450 CYP2J2
  • Cytochrome P-450 Enzyme System / genetics
  • Cytochrome P-450 Enzyme System / metabolism*
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism
  • Flow Cytometry
  • Humans
  • Lung / blood supply
  • Lung / drug effects*
  • Lung / physiopathology
  • Male
  • Membrane Potential, Mitochondrial / drug effects
  • Oxidative Stress / drug effects*
  • Oxidative Stress / genetics
  • Oxygen / metabolism
  • Oxygen / pharmacology
  • Protective Agents / pharmacology
  • Rats, Wistar
  • Reactive Oxygen Species / metabolism
  • Reperfusion Injury / genetics
  • Reperfusion Injury / physiopathology
  • Reperfusion Injury / prevention & control*

Substances

  • 14,15-dihydroxyeicosatrienoic acid
  • CYP2J2 protein, human
  • Protective Agents
  • Reactive Oxygen Species
  • Cytochrome P-450 Enzyme System
  • Cytochrome P-450 CYP2J2
  • 8,11,14-Eicosatrienoic Acid
  • Oxygen